A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 After Repeated Doses in Schizophrenic Patients. Relationship With Pharmacokinetics and Efficacy Readouts.
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Risperidone (Primary)
- Indications Psychotic disorders; Schizophrenia
- Focus Biomarker; Pharmacodynamics
- Acronyms SPECT
- 12 Oct 2008 Trial phase changed from II to I as reported by ClinicalTrials.gov
- 12 Oct 2008 Status changed from discontinued to completed.
- 26 Oct 2007 Status changed from in progress to discontinued